Where the stock stands
Aurobindo Pharma closed at 1648.2 rupees, down 2.09% from a previous close of 1683.3, a pullback after a strong run. The Nifty fell 0.59%, so the stock gave back a little more than the index on the day.
What the smart-money flow shows
Volume was light, with relative volume at 0.58, well below the stock's average, and the pack flags no notable institutional or derivative positioning. The dip looks like digestion of gains rather than a flow-driven exit.
The technical picture
The stock holds above both its 50-day and 200-day averages and sits just 1.96% under its 52-week high of 1717.0, with 65.66% of headroom above its 52-week low of 1016.1. It remains in an uptrend, up 8.27% over the past month, 15.01% over three months and 64.01% over the year, with a relative strength reading of 61.1.
Catalysts and what to watch
The regulatory overhang is the live item: CNBC TV18 reported the US FDA inspection at the AuroPeptides facility closed with one observation, a routine but watchable outcome for a business with large US exposure. Valuation is mid-range at a price-to-earnings ratio of 26.25 and a price-to-book of 2.53 on a 94834 crore rupee market cap, so the focus stays on whether the uptrend extends or consolidates near the highs.